Gawecka Ewa, Viken Oddbjørn
Oslo University Hospital, Department of Pain Management and Research, Rikshospitalet, Oslo, Norway.
Oslo University Hospital, Department of Anaesthesiology and Intensive Care Medicine, Rikshospitalet, Oslo, Norway.
Scand J Pain. 2012 Oct 1;3(4):220-228. doi: 10.1016/j.sjpain.2012.05.070.
Background and purpose Postherpetic neuralgia (PHN) is a complication of acute herpes zoster (HZ). The evidence base for management of PHN has increased by recent publications. Therefore, we reviewed incidence of HZ, prevalence, risk factors, and mechanism of PHN pain, prevention and treatment of PHN with special interest in studies on adult vaccination and topical application of lidocaine and concentrated capsaicin patch. Methods We searched databases with an English language restriction: MEDLINE 1944-2011, EMBASE 1988-2011, PubMed, and the Cochrane Controlled Trial Register and Cochrane Library (2011). From retrieved publications, we selected studies focusing on our main goals, prevention and treatment of PHN in particular. The review was therefore systematic, but with a pragmatic approach to which studies to select for closer review. Results From the large number of abstracts retrieved we selected 65 papers for closer review and as evidence base for our conclusions and recommendations for prevention and treatment of HZ and PHN. The incidence of HZ and risks of having PHN after HZ increases markedly with age above 60-70. Severity of symptoms and their impact on quality of life is a major health problem of persons above 70 years of age. Adult vaccination with the reinforced varicella virus vaccine reduces the incidence of HZ and PHN by about 50%. This is an important health and quality of life gain for the elderly. Antiviral drugs given early in an episode of HZ reduce pain and duration of HZ and decrease the risk of PHN. Pharmacological management of PHN are with nortriptyline (or amitriptyline in the younger patients), and or a gabapentinoid as first line drugs. Early treatment also is with topical lidocaine for immediate but short-lasting relief of burning hyperalgesia, and topical capsaicin relieving hypersensitivity for up to 12 weeks. A number of second and third line drugs have less evidence-base for effect, and often more adverse effects than the first line drugs: serotonin and noradrenaline uptake inhibitors (venlafaxin, duloxetin), antiepileptics (valproate), and opioid analgesics. Opioids are indicated for bridging in patients with severe PHN-symptoms while waiting for the more specific first line drugs to take effect. In these elderly patients, systemic pharmacological treatments are always a difficult balance between effects and adverse effects. It is important with close supervision of the patients, especially during start-up of systemically administered drugs, in order to prevent tragic complications from falls in sedated, dizzy, and confused elderly patients. Topical treatment with lidocaine and capsaicin patches does not have these problems. Conclusions Prevention of this significant health problem of the increasing elderly population is now possible through adult vaccination against varicella zoster virus (VZV) reactivation, as well as vigorous and early antiviral treatment during acute HZ. The evidence -base supports the oral use of tricyclic antidepressants, gabapentinoids, and opioids for bridging till the first line drugs take effect. Topical therapy with lidocaine and capsaicin patches is effective and well supported by evidence. A number of second and third line drugs and treatments are available, but have less evidence-base. All drug treatments, except topical lidocaine and capsaicin, have adverse effects that are often problematic and can be dangerous in the elderly patients. Close supervision of the patients is mandatory. Implications Recent advances in prevention and management of this serious health problem should be better known and implicated: Adult vaccination for prevention of varicella zoster virus reactivation, antiviral drugs and combinations of drugs can reduce the suffering from acute HZ and chronic PHN. Topical lidocaine and capsaicin are now evidence-based therapies that reduce suffering from hypersensitivity and hyperalgesia in patients with PHN. When properly applied, they have few complications.
带状疱疹后神经痛(PHN)是急性带状疱疹(HZ)的一种并发症。近期的出版物增加了PHN管理的证据基础。因此,我们回顾了HZ的发病率、患病率、危险因素、PHN疼痛的机制、PHN的预防和治疗,特别关注成人疫苗接种以及利多卡因和辣椒素浓缩贴片局部应用的研究。
我们检索了限定为英文的数据库:MEDLINE(1944 - 2011年)、EMBASE(1988 - 2011年)、PubMed以及Cochrane对照试验注册库和Cochrane图书馆(2011年)。从检索到的出版物中,我们选择专注于我们主要目标,特别是PHN预防和治疗的研究。因此,该综述是系统性的,但采用务实的方法来选择进行更深入审查的研究。
从大量检索到的摘要中,我们选择了65篇论文进行更深入审查,作为我们关于HZ和PHN预防与治疗的结论及建议的证据基础。HZ的发病率以及HZ后发生PHN的风险在60 - 70岁以上人群中显著增加。症状的严重程度及其对生活质量的影响是70岁以上人群的一个主要健康问题。接种强化水痘病毒疫苗可使HZ和PHN的发病率降低约50%。这对老年人来说是重要的健康和生活质量提升。在HZ发作早期给予抗病毒药物可减轻疼痛、缩短HZ病程并降低发生PHN的风险。PHN的药物治疗以去甲替林(年轻患者用阿米替林)和加巴喷丁类药物作为一线药物。早期治疗还包括局部使用利多卡因以立即但短暂缓解灼痛性痛觉过敏,以及局部使用辣椒素缓解超敏反应长达12周。一些二线和三线药物的疗效证据较少,且往往比一线药物有更多不良反应:5-羟色胺和去甲肾上腺素再摄取抑制剂(文拉法辛、度洛西汀)、抗癫痫药(丙戊酸盐)和阿片类镇痛药。阿片类药物适用于在等待更特效的一线药物起效期间用于缓解重度PHN症状的患者。在这些老年患者中,全身药物治疗始终是在疗效和不良反应之间艰难的平衡。密切监测患者非常重要,尤其是在开始全身用药期间,以防止镇静、头晕和意识模糊的老年患者因跌倒而发生悲惨并发症。局部使用利多卡因和辣椒素贴片不存在这些问题。
现在通过接种针对水痘带状疱疹病毒(VZV)再激活的成人疫苗以及在急性HZ期间积极早期抗病毒治疗,有可能预防这一老年人口中日益严重的健康问题。证据支持口服三环类抗抑郁药、加巴喷丁类药物和阿片类药物用于过渡直至一线药物起效。局部使用利多卡因和辣椒素贴片有效且有充分证据支持。有一些二线和三线药物及治疗方法,但证据较少。除局部使用利多卡因和辣椒素外,所有药物治疗都有不良反应,这些不良反应在老年患者中往往很成问题且可能很危险。必须密切监测患者。
应更好地了解和应用这一严重健康问题预防和管理方面的最新进展:成人接种疫苗预防水痘带状疱疹病毒再激活、抗病毒药物及联合用药可减轻急性HZ和慢性PHN的痛苦。局部使用利多卡因和辣椒素现在是基于证据的疗法,可减轻PHN患者的超敏反应和痛觉过敏。正确应用时,它们并发症较少。